Navigation Links
Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment
Date:1/7/2009

OXFORD, England, January 7 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on allergy and critical care, today announced that following successful clinical results achieved in 2008 with its ToleroMune(R) anti-allergy technology, the company has now completed patient recruitment for a further phase II clinical trial in cat allergy. The study, which is underway in Canada, has recruited 120 patients with confirmed cat allergies, and all the participants have completed screening and initial dosing with none experiencing any significant adverse events or safety issues. Circassia anticipates completing patient dosing in the next three months, with follow-up post-treatment challenge visits being completed by the end of April 2009.

The double-blind, randomized, placebo-controlled study is comparing several different ToleroMune treatment regimens, each with standardised doses administered over several weeks. This is in sharp contrast to most current allergy immunotherapies, which can require carefully titrated dosing over many months and even years. As part of the ongoing study, each patient is exposed to cat allergens in a controlled environmental exposure chamber both before and after receiving the study treatment. During these "challenges" the volunteers will monitor and record their allergic rhinitis symptoms to allow investigators to assess the effect of the ToleroMune treatment.

"We are delighted that this trial is making such rapid progress as it should define the optimal treatment approach for our ToleroMune cat-allergy therapy as it moves towards phase III testing," said Steve Harris, Circassia's CEO. "We are commited to introducing our ToleroMune treatment for cat allergy as quickly as possible because, despite its prevalence, the condition is poorly served by existing therapies due to their aggressive side-effect profile. ToleroMune offers allergists and their patients sig
'/>"/>

SOURCE Circassia Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Circassia Achieves Successful Phase II Clinical Results With Toleromune(R) Anti-Allergy Technology
2. Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
8. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
9. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
10. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
11. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... SAN DIEGO and CAMBRIDGE, Mass., May 28, ... LLP is investigating whether certain officers ... their fiduciary duties to shareholders.  Eleven Biotherapeutics is ... discovery and development of protein therapeutics to treat ... States .   View this ...
(Date:5/28/2015)... 28, 2015 Today, the California State Senate ... prescription database before prescribing the most addictive medications to ... deaths. SB 482, authored by Sen. ... will require prescribers to check the Controlled Substance Utilization ... and III drugs, like OxyContin and other opioids, for ...
(Date:5/28/2015)... , May 28, 2015   Eli Lilly and Company ... ) will host a webcast on June 11 to discuss ... baricitinib in rheumatoid arthritis. Data from these two trials, RA-BEACON and ... Programme for the EULAR Congress 2015 in Rome, ... from 10:00 to11:00 a.m. Eastern Daylight Time. The live audio ...
Breaking Medicine Technology:Robbins Arroyo LLP Is Investigating the Officers and Directors of Eleven Biotherapeutics, Inc. (EBIO) on Behalf of Shareholders 2California Senate Approves Legislation Requiring Physicians To Check State Database Before Prescribing Powerful, Addictive Medications, Says Consumer Watchdog 2Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data 2Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data 3
... CITY, Calif., Feb. 23, 2011 Abaxis, Inc. (Nasdaq: ... analysis systems, announced today that Clint Severson, chairman and chief ... Conference on Thursday, March 3, 2011 at 10:00 a.m. ET. ... Hotel in New York City. A live webcast ...
... Foundation and Vertex Pharmaceuticals announced today that VX-770, an oral ... cystic fibrosis, showed promising results in a Phase 3 clinical ... patients age 12 and up who carry at least one ... 161 patients who received at least one dose of VX-770 ...
Cached Medicine Technology:Abaxis, Inc. to Present at RBC Capital Markets' Healthcare Conference 2Phase 3 Study of VX-770 Shows Marked Improvement in Lung Function Among People with Cystic Fibrosis with G551D Mutation 2Phase 3 Study of VX-770 Shows Marked Improvement in Lung Function Among People with Cystic Fibrosis with G551D Mutation 3
(Date:5/28/2015)... May 28, 2015 Boston Celtics Legend ... Beth, both Genesis Foundation Board of Directors members, will ... Celebrity Fishing Tournament June 4-7. For the past 34 ... benefitting The Genesis Foundation for children by bringing together ... , The 34th John Havlicek Celebrity Fishing Tournament will ...
(Date:5/28/2015)... House, PA (PRWEB) May 28, 2015 ... Dalglish, today announced a just launched blog series which ... cultures. Hosted on the “R. Bruce Dalglish” profile ... decades of R. Bruce Dalglish’s corporate experience. , ... that positive workplace cultures have upon the overall success ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 Nidra Herbal Sleep ... gentle on the body. A non-addictive supplement, Nidra Herbal Sleep ... of natural ingredients will leave users with a real sense ... of care , Ayurveda, which translates as the “Science or ... 5,000 years ago and is a holistic system of knowledge ...
(Date:5/28/2015)... Baptist Medical Center Jacksonville has added a ... stroke or other neurological conditions. , The new Center ... in the country and the first in Florida designed ... brain aneurysms. , “Baptist Health is committed to ... are impacted by stroke,” said Nicole Thomas, Baptist Health ...
(Date:5/28/2015)... BC (PRWEB) May 28, 2015 ... Research ( http://www.idataresearch.com ), the shoulder reconstruction device ... orthopedic small bone & joint market in 2014. ... shoulder arthroplasty procedures in the U.S. due to ... improved device technology resulting in greater patient outcomes. ...
Breaking Medicine News(10 mins):Health News:The Genesis Foundation Prepares for Their Final Annual John Havlicek Celebrity Fishing Tournament 2Health News:R. Bruce Dalglish, CEO of Alliance Hospice, Introduces New Blog Series On Positive Corporate Culture 2Health News:Ayurveda Herba Corp’s Revolutionary Herbal Sleep Supplement is Now Available from Amazon.com 2Health News:Baptist Medical Center Jacksonville Adds Dedicated Neuro Emergency Unit 2Health News:Baptist Medical Center Jacksonville Adds Dedicated Neuro Emergency Unit 3Health News:DePuy Synthes and Biomet Lead Fastest Growing U.S. Shoulder Reconstruction Device Market 2Health News:DePuy Synthes and Biomet Lead Fastest Growing U.S. Shoulder Reconstruction Device Market 3
... of Atypicals In Major Depression Treatment Is Growing, ... Forecasts Between Pristiq and Effexor XR Need to ... 12 Decision Resources, one of the world,s ... and healthcare issues, finds that Forest Laboratories, Lexapro ...
... Charts Help Patients Manage Their Daily and Weekly MedicationsLAWRENCE, ... to improve the healthcare industry as a whole, it,s ... a difference on a smaller scale.Goss, a medical technologist, ... more. "I feel good about what I do in ...
... Winner Medical Group Inc.,s,(OTC Bulletin Board: WMDG; "Winner ... Co., Ltd., "Winner Shenzhen", and,Chengdu Likang Industries Co., ... venture in Chengdu, China to pursue medical dressing,product ... Likang is a subsidiary of West ...
... Recommended to Help Guide Important Conversations and Get Families ... The multi-disciplinary expert consortium known as the Alzheimer,s ... and friends to proactively start a dialogue with loved ... first sign of possible Alzheimer,s disease (AD) symptoms. The ...
... What we see determines what we do; and for ... are critical factors for better performance at school, at ... )To help parents, caregivers and others ... best, the American Optometric Association (AOA) Sports Vision Section ...
... 12 HeartWare International, Inc. (Nasdaq: HTWR ) ... an investor presentation at the Eighth Annual JMP Securities Research ... May 19, 2009. The conference is being held at ... the Company,s presentation at the conference will be available via ...
Cached Medicine News:Health News:Lexapro Loses First-Line Position for the Treatment of Major Depression 2Health News:Lexapro Loses First-Line Position for the Treatment of Major Depression 3Health News:Healthcare Professional Is Working to Make a Difference, One Dose at a Time 2Health News:Winner Medical Establishes Joint Venture With West China Hospital in Chengdu, China 2Health News:Winner Medical Establishes Joint Venture With West China Hospital in Chengdu, China 3Health News:Winner Medical Establishes Joint Venture With West China Hospital in Chengdu, China 4Health News:Experts Urge Family Members and Friends to Seek Immediate Intervention for Their Loved Ones Who May Have Alzheimer's Disease (AD) 2Health News:Experts Urge Family Members and Friends to Seek Immediate Intervention for Their Loved Ones Who May Have Alzheimer's Disease (AD) 3Health News:Experts Urge Family Members and Friends to Seek Immediate Intervention for Their Loved Ones Who May Have Alzheimer's Disease (AD) 4Health News:Experts Urge Family Members and Friends to Seek Immediate Intervention for Their Loved Ones Who May Have Alzheimer's Disease (AD) 5Health News:New 'Healthy Eyes for Peak Performance' Brochure Offers Parents and Caregivers Advice, Insight on the Role of Vision in Children's Performance 2Health News:HeartWare to Present at Eighth Annual JMP Securities Research Conference 2
Reusable shielded cable...
... A OIA MAX test delivers excellent sensitivity ... Strep with a simple, easy-to-use test that ... of performance, speed, and ease-of-use enables you ... overall costs for diagnosing and treating patients ...
The GC OIA test is a rapid assay for the diagnosis of gonorrhea. Thermo solved the challenge of developing a specific rapid assay for Neisseria gonorrhea by using the proprietary ribosomal protein, ...
... The FLU OIA test is a ... diagnosis of Influenza A and B with ... answer in just over 15 minutes. Assay ... specimen flexibility, and performance equivalent to 14-day ...
Medicine Products: